MedTrace Logo

D4 Choline Breast PET/CT

NCT04276272 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2024-08-26

No results posted yet for this study

Summary

The aim of this study is to evaluate the effect of CDK4/6 inhibitor treatment on the tumour choline metabolism as determined by \[18F\]D4-FCH PET/ computed tomography(CT) in breast cancer and to determine the suitability of \[18F\]D4-FCH-PET/CT as a non-invasive, early imaging biomarker for therapy response following CDK4/6 inhibitor treatment.

Conditions

Interventions

OTHER

Imaging scan

PET/CT scan

Sponsors & Collaborators

Principal Investigators

  • Laura Kenny · Imperial College London

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-24
Primary Completion
2023-11-03
Completion
2023-11-03

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04276272 on ClinicalTrials.gov